衰弱患者接受BCMA导向双特异性抗体治疗复发/难治性多发性骨髓瘤的结局
两组全级别细胞因子释放综合征、免疫效应细胞相关神经毒性综合征及治疗相关死亡率无显著差异,最佳总体缓解率分别为80%与73%(P=.40),中位无进展生存期与总生存期亦无显著差异。
要点
- 衰弱组与非衰弱组全级别细胞因子释放综合征发生率分别为58%与60%(P=.99)。
- 衰弱组最佳总体缓解率80%,非衰弱组73%(P=.40)。
- 中位随访8.6个月,两组中位无进展生存期与总生存期无显著差异。
核心结论
- BCMA导向双特异性抗体被认为对老年和衰弱复发/难治性多发性骨髓瘤患者安全有效。
研究设计与样本
- 单中心回顾性研究,纳入102例接受BCMA导向双特异性抗体治疗的复发/难治性多发性骨髓瘤患者,年龄范围40-88岁。
- 衰弱采用基于年龄、东部肿瘤协作组体能状态评分和Charlson共病指数的简化衰弱指数定义,非衰弱评分0-1分,衰弱评分≥2分。
主要发现
- 102例中40例(39%)为衰弱。
- 衰弱组年龄≥70岁者占73%,非衰弱组占29%(P<.001)。
- 衰弱组东部肿瘤协作组体能状态评分≥2者占36%,非衰弱组占0%(P<.001)。
- 衰弱组中位Charlson共病指数为2,非衰弱组为1(P<.001)。
- 衰弱组全级别细胞因子释放综合征发生率58%,非衰弱组60%(P=.99);免疫效应细胞相关神经毒性综合征发生率15%对8%(P=.44);治疗相关死亡率13%对21%(P=.27)。
关键数值与推荐
- 衰弱组最佳总体缓解率80%(严格完全缓解/完全缓解15%,非常好的部分缓解48%),非衰弱组73%(严格完全缓解/完全缓解23%,非常好的部分缓解31%)(P=.40)。
- 中位随访8.6个月(范围3-14),衰弱组与非衰弱组中位无进展生存期未达到对11个月(P=.051),中位总生存期37个月对25个月(P=.37)。
临床怎么用
- 原文结论认为BCMA导向双特异性抗体对老年和衰弱复发/难治性多发性骨髓瘤患者安全有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with relapsed/refractory (R/R) multiple myeloma (MM) are often frail with preexisting comorbidities and poor performance status (PS). To evaluate clinical characteristics and outcomes based on frailty, we conducted a single-center retrospective study of patients with R/R MM who received B-cell maturation antigen (BCMA)-directed bispecific antibodies (BsAbs). Frailty was defined using the simplified frailty index based on age, Eastern Cooperative Oncology Group (ECOG) PS, and Charlson comorbidity index (CCI; nonfrail score 0-1 and frail score ≥2). Of 102 patients analyzed (age range, 40-88 years), 40 (39%) were considered frail. The frail group had more patients aged ≥70 years (73% vs 29%; P < .001), with ECOG PS ≥2 (36% vs 0%; P < .001), and worse median CCI (2 vs 1; P < .001). Patients in the frail group experienced similar rates of all-grade cytokine release syndrome (58% vs 60%; P = .99), immune effector cell-associated neurotoxicity syndrome (15% vs 8%; P = .44), and treatment-related mortality (13% vs 21%; P = .27) compared to the nonfrail group. The best overall response rate was 80% (stringent complete response [sCR]/CR, 15%; very good partial response [VGPR], 48%) in the frail group vs 73% (sCR/CR, 23%; VGPR, 31%) in the nonfrail group (P = .40). With a median follow-up of 8.6 months (range, 3-14), there was no significant difference in median progression-free survival (not reached vs 11 months; P = .051) or overall survival (37 vs 25 months; P = .37) between the frail and nonfrail groups. Hence, BsAbs were deemed safe and effective for older and frail patients with R/R MM.
引用
- Adegbite B, Tan CR, Shekarkhand T, et al. Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma. Blood Adv. 2025. PMID: 40315372. doi:10.1182/bloodadvances.2025015973
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。